In its continued effort to lead the community through the COVID-19 pandemic, The Hospitals of Providence continues to administer the COVID-19 monoclonal antibody infusion treatment in individuals 12 years of age and older to reduce the risk of patients needing to be hospitalized or becoming severely ill with COVID-19.
“The health and well-being of our community remains our highest priority and as we begin to see an increase in COVID-19 cases we are focused on ensuring these types of therapies are readily available to help protect our family, friends and loved ones from becoming severely ill,” said Nicholas Tejeda, Group CEO for The Hospitals of Providence.
“This infusion treatment has proven itself to be an effective tool to reduce the severity of symptoms in COVID-19 patients, as well as a preventative treatment for patients who have been exposed to someone with COVID-19 and they themselves are at a high-risk of becoming severely ill with COVID-19 – our goal is to reduce the need for patients to be hospitalized.”
The monoclonal antibody infusion treatment is now available as a preventative measure for individuals who are at risk of becoming severely ill from COVID-19 or have not been fully vaccinated and have been exposed to a COVID-19 positive individual.
The Hospitals of Providence is the only El Paso provider to offer the monoclonal antibody infusion treatment. All infusion treatments are administered at the Memorial Campus.
Monoclonal antibody infusion treatment is intended for patients who meet the following criteria:
- Have been exposed or been in close contact to an individual who is COVID-19 positive and you are at high risk for progression of severe COVID-19
- Tested positive for COVID-19
- Non-hospitalized adults and adolescents 12 years of age and older
- Mild to moderate symptoms
- Within 10 days of symptom onset
Patients who have received a positive test result for COVID-19 OR patients who have come in close contact with an individual who is COVID-19 positive and are at risk of developing severe illness, should talk with their doctor or healthcare provider to see if monoclonal antibody infusion treatment is right for them.